Sign inJoin waitlistJoin the waitlist

Suzanne Shusterman

Assistant Professor of Pediatrics, Harvard Medical School · Mass General Brigham

Credentials: · · ·

History

Mass General Brigham
Present

Pediatric Hematology Oncology
Children's Hospital of Philadelphia
1996–1999
Pediatrics
Boston Children's Hospital
1993–1996
University of Massachusetts T.H. Chan School of Medicine
1989–1993

Research

Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study
Journal of Clinical Oncology · 2010 · First of 19 authors · 187 citations
Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study
JAMA Oncology · 2016 · 177 citations
Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number
Cancer Research · 2006 · 157 citations

John Maris
18 papers
Steven DuBois
16 papers
Rochelle Bagatell
12 papers
Julie Park
9 papers
Lisa Diller
9 papers
Yael Mosse
8 papers · 3 as a fellow
Araz Marachelian
7 papers
Kieuhoa Vo
7 papers
Meaghan Granger
7 papers
Susan Cohn
7 papers
JB
Julia Bender
6 papers
Katherine Janeway
6 papers

Clinical trials

Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma
Principal investigator · Completed · Phase 2
Children's Oncology Group
2011–2019
hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma
Study chair · Completed · Phase 2
Children's Oncology Group
2005–2012
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2029
A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects
Site PI · Unknown · Phase 2
Jubilant DraxImage Inc.
2019–2025